UNSPSC 51411607: Propatylnitrate

This classification denotes a vasodilating agent with the molecular formula C6H11N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AJT2YN495R, chemically known as 1,3-propanediol, 2-ethyl-2-((nitrooxy)methyl)-, dinitrate (ester) but generally known as propatyl nitrate, which bears US NIH Compound Identifier 66261. European Medicines Agency schedules Propatylnitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10099MIG. The term PROPATYL NITRATE is an International Non-Proprietary Name.

World Health Organization schedules propatyl nitrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule propatylnitrate under HS 29209085 and SITC 51639. SMILES: CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]

UNSPSC 51411607 Propatylnitrate is a Commodity code representing individual pharmaceutical products supplied to state and local health care, emergency medical, and public health programs. State and local governments procure this and related advanced life support medications through sealed competitive bids, cooperative purchasing agreements, and market-intelligence initiatives to stock emergency response fleets, hospital systems, and pharmacy benefit programs. The code encompasses both direct manufacturer supply arrangements and distribution through authorized wholesalers, with emphasis on firm pricing, expiration-date management, product traceability, and regulatory compliance including FDA certification, Good Manufacturing Practices, and Drug Supply Chain Security Act conformance.

Issuing bodies include city purchasing departments (Tampa Fire Rescue), state health agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple participating states including Oregon). Recent opportunities reflect geographic concentration in the South and Upper Midwest. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with a response date of April 8, 2026 and estimated contract value of $40,000, featuring a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response date, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and maintain $5,000,000 commercial general liability insurance. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to explore direct-to-manufacturer prescription capabilities outside traditional PBM and GPO channels, signaling preliminary market research before formal solicitation.